1. |
Ortiz MV, Dunkel IJ. Retinoblastoma. J Child Neurol, 2016, 31(2): 227-236.
|
2. |
PDQ Pediatric Treatment Editorial Board. Retinoblastoma treatment (PDQ®): health professional version. (2016-03-14)[2016-07-31]. https://www.ncbi.nlm.nih.gov/pubmed/26389442.
|
3. |
Kim JY, Park Y. Treatment of retinoblastoma: the role of external beam radiotherapy. Yonsei Med J, 2015, 56(6): 1478-1491.
|
4. |
Li WL, Buckley J, Sanchez-Lara PA, et al. A rapid and sensitive next-generation sequencing method to detect RB1 mutations improves care for retinoblastoma patients and their families. J Mol Diagn, 2016, 18(4): 480-493.
|
5. |
Imhof SM, Mourits MP, Hofman P, et al. Quantification of orbital and mid-facial growth retardation after megavoltage external beam irradiation in children with retinoblastoma. Ophthalmology, 1996, 103(2): 263-268.
|
6. |
Shields CL, Lally SE, Leahey AM, et al. Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol, 2014, 25(5): 374-385.
|
7. |
Chung CY, Medina CA, Aziz HA, et al. Retinoblastoma: evidence for stage-based chemotherapy. Int Ophthalmol Clin, 2015, 55(1): 63-75.
|
8. |
Shields CL, Fulco EM, Arias JD, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond), 2013, 27(2): 253-264.
|
9. |
Brennan RC, Qaddoumi I, Billups CA, et al. Patients with retinoblastoma and chromosome 13q deletions have increased chemotherapy-related toxicities. Pediatr Blood Cancer, 2016, 63(11): 1954-1958.
|
10. |
Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res, 1987, 78(8): 858-868.
|
11. |
Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthal, 2011, 129(6): 732-737.
|
12. |
Vajzovic LM, Murray TG, Aziz-Sultan MA, et al. Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma. Clin Ophthalmol, 2011, 5(5): 171-176.
|
13. |
Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol, 2003, 121(8): 1120-1124.
|
14. |
Tuncer S, Balcı Ö, Tanyıldız B, et al. Intravitreal Lower-Dose (20 μg) melphalan for persistent or recurrent retinoblastoma vitreous seeds. Ophthalmic Surg Lasers Imaging Retina, 2015, 46(9): 942-948.
|
15. |
Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives. Saudi J Ophthalmol, 2013, 27(3): 147-150.
|
16. |
Francis JH, Abramson DH, Gaillard MC, et al. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology, 2015, 122(6): 1173-1179.
|
17. |
Ji X, Hua P, Li J, et al. Intravitreal melphalan for vitreous seeds: initial experience in China, 2016: 4387286.
|
18. |
Francis JH, Xu XL, Gobin YP, et al. Death by water: precautionary water submersion for intravitreal injection of retinoblastoma eyes. Open Ophthalmol J, 2014, 8: 7-11.
|
19. |
Rodriguez-Galindo C, Chantada GL, Haik BG, et al. Treatment of retinoblastoma: current status and future perspectives. Curr Treat Options Neurol, 2007, 9(4): 294-307.
|
20. |
Chawla B, Jain A, Azad R. Conservative treatment modalities in retinoblastoma. Indian J Ophthalmol, 2013, 61(9): 479-485.
|
21. |
Finger PT, Czechonska G, Demirci H, et al. Chemotherapy for retinoblastoma. Arch Ophthalmol, 1999, 58(6): 983-996.
|
22. |
Mendoza PR, Grossniklaus HE. Therapeutic options for retinoblastoma. Cancer Control, 2016, 23(2): 99-109.
|
23. |
Zhang J, Benavente CA, Mcevoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature, 2012, 481(7381): 329-334.
|
24. |
Wen X, Lu L, He Z, et al. Orchestrating epigenetic roles targeting ocular tumors. Onco Targets Ther, 2016, 9(9): 1001-1009.
|
25. |
Tamboli D, Topham A, Singh N, et al. Retinoblastoma: a SEER dataset evaluation for treatment patterns, survival, and second malignant neoplasms. Am J Ophthalmol, 2015, 160(5): 953-958.
|
26. |
de Jong MC, Kors WA, de, Graaf P. The incidence of trilateral retinoblastoma: a systematic review and meta-analysis. Am J Ophthalmol, 1994, 160(6): 51-52.
|
27. |
Abramson DH, Shields CL, Munier FL, et al. Treatment of retinoblastoma in 2015: agreement and disagreement. JAMA Ophthalmol, 2015, 133(11): 1341-1347.
|
28. |
Gobin YP, Dunkel IJ, Marr BP, et al. Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS One, 2012, 7(9): e44322.
|